

2015 Venice Arrhythmia

Core Curriculum:
Arrhythmogenic genetic syndrome: what's new?
Brugada Syndrome: What's new?

October 16th, 2015

Venice, Italy

**Variants of Brugada Syndrome:
the evolving picture**

**Wataru Shimizu M.D., Ph.D.
Nippon Medical School, Tokyo, Japan**



Nippon Medical School




Conflicts of Interest: Wataru Shimizu

- | | |
|--|--|
| ①Consultation fees: | none |
| ②stock ownership/profit: | none |
| ③patent fees: | none |
| ④remuneration for lecture: | Daiichi Sankyo., Ltd.
Tanabe Mitsubishi Pharma Corporation
Nippon Boehringer Ingelheim Co., Ltd.
Bayer Yakuhin, Ltd.
Bristol-Myers K.K.
Pfizer Japan Inc.
Ono Pharma Corporation |
| ⑤manuscript fees: | none |
| ⑥trust research/joint research funds: | none |
| ⑦scholarship fund: | Daiichi Sankyo., Ltd.
Tanabe Mitsubishi Pharma Corporation
Nippon Boehringer Ingelheim Co., Ltd.
Bristol-Myers K.K. |
| ⑧Affiliation with Endowed Department: | none |
| ⑨Other remuneration such as gifts: | none |

Idiopathic VF with J wave and ST elevation in the inferior leads: Brugada Syndrome Variants ?


- Takagi M, Shimizu W. et al JCE 2000
- Kalla H. et al JCE 2000



Early repolarization pattern in infero/lateral leads


- Sudden cardiac arrest associated with early repolarization

(Haissaguerre M. et al NEJM 2008)



Idiopathic VF with J wave and ST elevation in the inferior leads: Brugada Syndrome Variants ?


- Takagi M, Shimizu W. et al JCE 2000
- Kalla H. et al JCE 2000



Japanese Brugada Registry

Kamakura S, Shimizu W, et al. Circ Arrhythm Electrophysiol 2009; 2: 495-503.

Early Repolarization in infero-lateral leads




N. of pts. with early repolarization

Early Rep -	219	214	197	166	155	127	63
Early Rep +	26	23	19	19	17	12	9

- Brugada patients associated with early repolarization in infero-lateral leads showed poorer prognosis than those without.

Type 1 Brugada patient with infero-lateral ER

Kawata H, Shimizu W et al. Heart Rhythm 2013;10:1161-1168




National Cerebral and Cardiovascular Center



Nippon Medical School

Survival Curve of Brugada patients with VF document depending on presence and frequency of infero-lateral ER

Kawata H, Shimizu W et al. Heart Rhythm 2013;10:1161-1168



Number of patients

Persistent

0
12

Follow up duration (months)
24
36
48

60

Intermittent

15
8

4
3
2
0

Non

16
9

7
6
5
4

18
14

13
12
11
10



National Cerebral and Cardiovascular Center



Nippon Medical School

Similarities between Brugada syndrome and ERS


Shimizu W et al. Unpublished data

- Male predominance
- Late adulthood onset
- Genotype
- More frequent ventricular arrhythmias during sleep and rest than during physically active periods
- Dynamicity of the J-point elevation in an ER pattern and ST-segment elevation in a Brugada ECG
- Pause- and bradycardia-dependent augmentation of the J-point elevation in the ER pattern and ST-segment elevation in the Brugada ECG
- Response to pharmacological therapy (Isoproterenol, Quinidine, Bepridil, Denopamine, Cilostazol)



J wave syndrome

Antzelevitch C. Heart Rhythm. 2010; 7: 549-558.



Brugada syndrome

Inferolateral ERS


- Brugada syndrome (BrS) and ERS are considered to share a similar characteristics and to represent a continuous spectrum of phenotypic expression termed J-wave syndrome.

Japanese Brugada Registry

Kamakura S, Shimizu W, et al. Circ Arrhythm Electrophysiol 2009; 2: 495-503.

J wave amplitude =
1.6mm (< 2.0mm)

Non type 1 ECG



- We also reported in Japanese Brugada Registry that patients with **non-type 1 ST-segment elevation (ER pattern) in standard V1-V2 leads** even after drug provocation test show poor prognosis, just as patients with type 1 Brugada syndrome.

Diagnosis of Brugada Syndrome

Priori SG, Wilde AA, Krahn A, Shimizu W, et al. Europace 15(10): 1389-1406, 2013.

BrS is diagnosed when a type-1 ST-segment elevation is observed

Diagnostic criteria 2005

- At least 2 right precordial leads (V_1 to V_3)
- Standard 12-lead ECG
- Spontaneously or after drug challenge test by a sodium channel blocking agent

Consensus statement in 2013

- At least 1 right precordial lead (V_1 and V_2)
- Standard or a higher position (up to the 2nd intercostal space)
- Spontaneously or after drug challenge test by a sodium channel blocking agent




Hypothesis

Kamakura S, Shimizu W, et al. Circ Arrhythm Electrophysiol 2009; 2: 495-503.

J wave amplitude =
1.6mm (< 2.0mm)

Non type 1 ER pattern




- Patients with **non-type 1 ER (NT1-ER)** in high costal (2nd and 3rd) ECG recordings may be another variant of Brugada syndrome.
- Therefore, we compared the clinical profile and long-term prognosis between patients with and without **NT1-ER** in high costal (2nd and 3rd) ECG among infero-lateral ERS patients.

Methods

Kamakura T, Shimizu W et al. J Am Coll Cardiol 2013; 62:1610-1618.


- 31 patients (27 men, mean age: 42.0 ± 14.1 years) with infero-lateral ERS and a prior episode of VF were divided into 2 groups.
 - baseline and high costal (2nd and 3rd) ECG recordings
 - drug provocation tests with a sodium channel blocker (pilsicainide 1mg/kg)
- ✓ **ERS[A]-group (n=12) : patients with an inferolateral ER combined with NT1-ER**



- Clinical profiles and VF recurrences during follow-up were compared among ERS(A) group, ERS(B) group, 40 patients with Brugada syndrome and a history of VF (BS group), and 13 patients with idiopathic VF without J waves (IVF group).

ERS (A) group

Kamakura T, Shimizu W et al. J Am Coll Cardiol 2013; 62:1610-1618.




National Cerebral and Cardiovascular Center



Nippon Medical School

ERS (B) group

Kamakura T, Shimizu W et al. J Am Coll Cardiol 2013; 62:1610-1618.



Clinical Characteristics

Kamakura T, Shimizu W et al. J Am Coll Cardiol 2013; 62:1610-1618.

Group	ERS (n=31)				P value (A) vs. (B)
	ERS (A) (n=12)	ERS(B) (n=19)	BS (n=40)	IVF (n=13)	
Age (years)	41.2 ± 11.4	42.5 ± 15.8	43.0 ± 12.2	46.1 ± 12.7	0.60
Men n, (%)	9 (75%)	18 (95%)	40 (100%)	8 (62%)	0.27
FH of SCD n, (%)	1 (8%)	0 (0%)	8 (20%)	2 (15%)	0.39
VF/CA during sleep (%)	10 (8, 2) (83%)	2 (2, 0) (11%)	22 (17, 5) (55%)	1 (1, 0) (8%)	< 0.0001


Clinical Course

Kamakura T, Shimizu W et al. J Am Coll Cardiol 2013; 62:1610-1618.

Group	ERS (n=31)				P value (A) vs. (B)
	ERS (A) (n=12)	ERS(B) (n=19)	BS (n=40)	IVF (n=13)	
Follow-up (months)	90 ± 57	76 ± 46	104 ± 63	82 ± 50	0.76
VF recurrence n, (%)	7 (58%)	2 (11%)	22 (55%)	2 (15%)	0.012
VF storm n, (%)	5 (42%)	0 (0%)	10 (25%)	0 (0%)	0.0047
ICD implantation n (%)	12 (100%)	18 (95%)	38 (95%)	10 (77%)	1.0

Kaplan-Meier analysis of free of VF

Kamakura T, Shimizu W et al. J Am Coll Cardiol 2013; 62:1610-1618.



Summary

Kamakura T, Shimizu W et al. J Am Coll Cardiol 2013; 62:1610-1618.

- Infero-lateral ERS patients can be divided into 2 heterogeneous groups:
 - Patients with pure infero-lateral ER
 - Patients with infero-lateral ER + non-type 1 ER pattern in high costal ECG.
- Non-type 1 ER pattern in high costal ECG seems to be a key predictor of poor outcome in patients with inferolateral ERS.

Patients with non-type 1 ER pattern in high costal ECG may be another variant of Brugada syndrome

J wave syndrome


Antzelevitch C. Heart Rhythm. 2010; 7: 549-558.

ERS

ERS1 (lateral- I, V4-V6): good prognosis

ERS2 (inferior- II, III, aVF)

ERS3 (global): poor prognosis




Brugada syndrome

Inferolateral ERS

Early repolarization syndrome (ERS)

Kamakura T, Shimizu W et al. J Am Coll Cardiol 2013; 62:1610-1618.



Acknowledgement

- Shiga Univ. School of Medical Science
Minoru Horie, Seiko Ohno
Hiroshi Matsuura, Futoshi Toyoda
- Keio University
Keiichi Fukuda, Shinsuke Yuasa
Yoshiyasu Aizawa
- Nagasaki University
Naomasa Makita
- Tokyo Medical and Dental University
Tetsushi Furukawa
Toshihiro Tanaka
- Niigata University
Hiroshi Watanabe
- Tokyo Womens Medical University
Nobuhisa Hagiwara
- Nihon University
Naokata Sumitomo
- Kanazawa University
Masakazu Yamagishi, Kenshi Hayashi
- Kyoto University
Takeru Makiyama
- Okayama University
Hiroshi Morita, Kazufumi Nakamura
- Kagoshima Medical Center
Masao Yoshinaga
- Tsukuba University
Hitoshi Horigome, Kazutaka Aonuma
- Nippon Medical School
Yasushi Miyauchi, Meiso Hayashi
- National Cerebral and Cardiovascular Center
Tsukasa Kamakura,
Shiro Kamakura,
Aiba Takeshi
Yoshihiro Miyamoto
Akihiro Sekine
Isao Shiraishi
Hisaki Makimoto
Hiro Kawata
Tsukasa Kamakura
Kenichiro Yamagata
Kohei Ishibashi
Ikutaro Nakajima
Koji Miyamoto
Hideo Okamura
Takashi Noda
Kengo F. Kusano
- Academic Medical Center, Amsterdam
Connie Bezzina
Arthur AM Wilde
- Tel-Aviv University, Israel
Sami Viskin
- Lankenau Institute for Medical Research, USA
Charles Antzelevitch

Thank you for your attention